This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Public Health, Other  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Neoplasms  • Dermatologic Disorders, Other  • Public Health  • Alert me on articles by topic

Graça M. Dores, MD, MPH; Rochelle E. Curtis, MA; William F. Anderson, MD, MPH; Marie-France Demierre, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Using data from the Surveillance, Epidemiology and End Results Program (SEER), Criscione and Weinstock¹ described increasing incidence rates (IRs) for cutaneous T-cell lymphoma (CTCL) in the United States. The authors speculate that IRs may be underestimated owing to possible underregistration and delayed reporting. Underregistration or underreporting is difficult to assess; however, delayed reporting can be evaluated in SEER.^2-3 Delayed reporting refers to cases submitted by SEER to the National Cancer Institute (NCI) after an allowable ascertainment period. Before submitting data to NCI, SEER registries have a 2-year period to collect information on all newly diagnosed cancer cases. Cases collected after this 2-year ascertainment period are reported on subsequent data submissions, thereby resulting in revised estimates of IRs for the earlier time period.²

Herein, we assess delayed reporting of mycosis fungoides and Sézary syndrome . . . [Full Text of this Article]

AUTHOR INFORMATION